Aguettant,
pharmaceutical company

Aguettant is an integrated laboratory and expert in essential drugs for injection in hospitals. We master all stages of creating an essential medicine, from R&D to marketing, to enable healthcare professionals to treat their patients in critical situations in an optimal way.
FR VIDEO LABORATOIRE PHARMACEUTIQUE frame at 0m15s
See the video

A french family business...

an international reach

derush.00 28 54 03.Still279
guillemets Aguettant is an independent and family-owned French pharmaceutical laboratory, an expert in the field of injectable drugs.

Our mission is to contribute to the care of patients, particularly in hospitals, by providing health professionals with essential injectable drugs adapted to the requirements of medical practice.

The combination of our strengths makes our difference. Our ability to innovate in administration systems, our national industrial infrastructure with multiple technologies, our growing international commercial development coupled with our strong exposure to hospital governance challenges us and makes us strive for a higher standard. To this is added a recent diversification in in vitro diagnostics, completing the field of our possibilities.

The strength of the values ​​and commitment of our employees produce concrete achievements, whether they are part of the response to a pandemic, the participation in health and industrial sovereignty or the humble but decisive contribution to the care of a patient hospitalized in intensive care, here or elsewhere.

To you, health professionals, regulatory authorities, manufacturers, commercial companies, decision-makers in the world of health, future collaborators, know that the teams of Laboratoire Aguettant are proud to be at your side, driven by our mission and with constant focus on the essential. guillemets
Éric Rougemond
CEO of Aguettant

In

France

Aguettant has set up its headquarters and its 5 industrial sites (including 1 R&D center of excellence) in the Auvergne Rhône-Alpes region :
- Lyon, 2 sites
- Saint-Fons
- Champagne
- Grenoble R&D center
Aguettant is also engaged in a continuous investment in innovation and development of its industrial capacities. This ambitious approach serves both the strategic ambition of the company and the aspirations of the public authorities to keep French businesses in France.
Our industrial sites
carte France aguettant v2

Internationally

10 commercial affiliates :
- France
- Germany & Austria
- Italy
- Benelux
- Nordics
- Spain & Portugal
Switzerland
UK & Ireland

and distribution in more than 70 countries.
Our commercial affiliates
carte monde sans legende aguettant en

Governance

Most of the Group's business operations are present in France. They are managed by the Executive Committee :
/ 2
Sebastien Aguettant

Sébastien

AGUETTANT

Chairman of the Supervisory Board
eric rougemond

Eric

ROUGEMOND

Chairman of the Board
Chief commercial officer (acting)
delphine fornas

Delphine

FORNAS

Scientific and Regulatory Affairs & Market access Chief Officer
eric tort

Eric

TORT

General secretary
Guillaume sabatier

Guillaume

SABATIER

Chief Operations Officer
Head Pharmacist
/ 5

The story

of a commitment

From the beginnings as a drugstore to the evolution into an internationalized pharmaceutical laboratory, our history testifies to our desire to innovate, our objective always being the same: to offer patients and caregivers essential drugs that contribute to better care.
Learn more
Georges Aguettant sans legende Fondateur du laboratoire Aguettant
Georges Aguettant - Founder of the Aguettant Laboratory

Sustainable

development

In 2022, Aguettant received for the second consecutive year the ECOVADIS silver medal for its performance on the aspects of Corporate Social Responsibility.
Learn more
Cyclistes Aguettant
This site was designed and created by the agency customR in a sustainable way, with technologies to reduce its carbon impact. It produces only 0.2g of CO2 per page viewed and is powered by renewable energy. Carbon calculations were done with websitecarbon.
INT 175/00 Septembre 2023
Last update of the site : 

October 16, 2023

chevron-uparrow-right